Abstract
D-TYPE cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the Gl phase of the cell cycle1–6 by phosphorylating the retinoblastoma protein (RB)7,8. The activities of Cdk4 and Cdk6 are constrained by inhibitors9–12 such as pi6, the product of the CDKN2 gene on human chromosome 9p21 (refs 12–14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that pi6 acts as a tumour suppressor. We show that wild-type pi6 arrests normal diploid cells in late Gl, whereas a tumour-associated mutant of pi6 does not. Significantly, the ability of pi6 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of pi6, overexpression of D-cyclins and loss of RB have similar effects on Gl progression, and may represent a common pathway to tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baldin, V., Lukas, J., Marcotte, M. J., Pagano, M. & Draetta, G. Genes Dev. 7, 812–821 (1993).
Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
Quelle, D. E. et al. Genes Dev. 7, 1559–1571 (1993).
Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
Musgrove, E. A., Lee, C. S. L., Buckley, M. F. & Sutherland, R. L. Proc. natn. Acad. Sci. U.S.A. 91, 8022–8026 (1994).
Resnitzky, D., Gossen, M., Bujard, H. & Reed, S. I. Molec. cell. Biol. 14, 1669–1679 (1994).
Hunter, T. & Pines, J. Cell 79, 573–582 (1994).
Sherr, C. J. Cell 79, 551–555 (1994).
Guan, K.-L. et al. Genes Dev. 8, 2939–2952 (1994).
Hannon, G. J. & Beach, D. Nature 371, 257–261 (1994).
Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
Serrano, M., Hannon, G. J. & Beach, D. Nature 366, 704–707 (1993).
Kamb, A. et al. Science 264, 436–440 (1994).
Nobori, T. et al. Nature 368, 753–756 (1994).
Okamoto, A. et al. Proc. natn. Acad. Sci. U.S.A. 91, 11045–11049 (1994).
Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
Parry, D., Bates, S., Mann, D. J. & Peters, G. EMBO J. 14, 503–511 (1995).
Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E. & Sherr, C. J. Genes Dev. 7, 331–342 (1993).
Lukas, J. et al. J. Cell Biol. 125, 625–638 (1994).
Serrano, M., Gómez-Lahoz, E., DePinho, R. A., Beach, D. & Bar-Sagi, D. Science 267, 249–252 (1995).
Lukas, J. et al. Oncogene (in the press).
van den Heuvel, S. & Harlow, E. Science 262, 2050–2054 (1993).
Clarke, A. R. et al. Nature 359, 328–330 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lukas, J., Parry, D., Aagaard, L. et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503–506 (1995). https://doi.org/10.1038/375503a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/375503a0
This article is cited by
-
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development
Experimental Hematology & Oncology (2023)
-
Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation
Cell Death & Disease (2023)
-
Bone morphogenetic protein 4 rescues the bone regenerative potential of old muscle-derived stem cells via regulation of cell cycle inhibitors
Stem Cell Research & Therapy (2022)
-
Rad54L promotes bladder cancer progression by regulating cell cycle and cell senescence
Medical Oncology (2022)
-
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Nature Communications (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
